Table 3.
Results of pooling odds ratio and risk ratio of includied studies
| Type of autoimmune disease | Cross-sectional/case–control studies | Cohort studies | ||||
|---|---|---|---|---|---|---|
| Studies(n) | Case/control(n) | OR (95% CI) | Studies(n) | Case/control(n) | RR (95% CI) | |
| Alopecia areata | 4 | 87,139,761/88,638,587 | 9.72 (4.38–21.59) | 3 | 1,443,111/2,410,018 | 2.98 (1.36–6.53) |
| Systematic lupus erythematosus | 4 | 88,496,787/89,412,647 | 1.74 (1.34–2.19) | 2 | 1,585,927/2,940,046 | 2.20 (1.44–3.38) |
| Vitiligo | 6 | 88,529,196/ 89,676,032 | 3.61 (2.31–5.63) | 2 | 1,402,804/2,248,790 | 1.64 (1.27–2.13) |
| Celiac disease | 4 | 88,571,653/89,361,659 | 1.98 (1.51–2.60) | 1 | 1,393,570/2,170,618 | 1.41 (1.32–1.50) |
| Crohn’s disease | 5 | 87,101,613/87,416,984 | 1.66 (1.50–1.84) | 3 | 3,000,852/2,776,586 | 1.38 (1.17–1.63) |
| Ulcerative colitis | 5 | 87,101,613/87,416,984 | 1.95 (1.57–2.44) | 2 | 1,607,282/8,972,054 | 1.49 (1.05–2.11) |
| Rheumatoid arthritis | 5 | 88,527,141/89,675,474 | 1.18 (1.01–1.37) | 3 | 1,462,324/2,946,824 | 1.38 (1.16–1.63) |